{"id":133,"date":"2025-12-09T12:25:37","date_gmt":"2025-12-09T12:25:37","guid":{"rendered":"https:\/\/ikrispharmainternational.com\/blog\/?p=133"},"modified":"2025-12-12T06:38:11","modified_gmt":"2025-12-12T06:38:11","slug":"global-access-to-unapproved-drugs","status":"publish","type":"post","link":"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/","title":{"rendered":"Global Access to Unapproved Drugs"},"content":{"rendered":"\n<p>In some scenarios, patients around the world need unlicensed or unapproved medicines<strong>. <\/strong>This happens when standard treatments have failed or are not yet available in their home country. Healthcare is changing quickly, and <strong><a href=\"https:\/\/ikrispharmainternational.com\/named-patient-program\">Global Access to Unapproved Drugs<\/a><\/strong> is becoming important, as new medicines are approved every year by authorities like the <strong>U.S. FDA, EMA, MHRA, CDSCO, TGA,<\/strong> and others But these medicines may take a little more time to reach every country.<\/p>\n\n\n\n<p>Because of this delay, zillions of patients, particularly those with <strong>serious, life-threatening, or rare diseases<\/strong>, look for access to these new medicines. For such a population, accessing an unapproved or unlicensed drug can become an important support system.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What Are <strong>Unapproved<\/strong> Medicines?<\/strong><\/h2>\n\n\n\n<p><strong>Unapproved medicines<\/strong> (also called unlicensed, unregistered, or <strong>non-marketed drugs<\/strong>) are medicinal products that:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Are <strong>not authorized for distribution<\/strong> in a specific country<\/li>\n\n\n\n<li>Have <strong>not received national marketing approval<\/strong><\/li>\n\n\n\n<li>May be approved in the <strong>US, EU, UK, Japan, India, or other regions<\/strong><\/li>\n\n\n\n<li>Are still under evaluation\/review or in late-stage clinical testing<\/li>\n\n\n\n<li>Are for <strong>rare diseases, small patient groups, or unmet medical needs<\/strong><\/li>\n<\/ul>\n\n\n\n<p>Even though such medicines are not sold in a country, patients can <strong>legally access them<\/strong> through <strong>regulated import pathways<\/strong> when no other treatment is unavailable or unapproved.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Why Do Some Medicines Remain Unapproved in Certain Countries?<\/strong><\/h2>\n\n\n\n<p>There are many reasons why a medicine may not be available or authorized in a particular country:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The manufacturing company has <strong>not applied<\/strong> for national approval<\/li>\n\n\n\n<li>Local health authorities require <strong>more clinical or safety information<\/strong><\/li>\n\n\n\n<li>The drug is meant for a <strong>rare or ultra-rare disease<\/strong> with less demand<\/li>\n\n\n\n<li>The medicine is approved only in the <strong>company\u2019s main countries<\/strong>, not everywhere<\/li>\n\n\n\n<li>Issues such as pricing, reimbursement, or regulatory systems can slow down or delay the launch.<\/li>\n\n\n\n<li>The medicinal product has recently been approved in other countries and has not yet been launched locally<br><\/li>\n<\/ul>\n\n\n\n<p>This causes a treatment gap that affects urgent access to unapproved, unregistered, or <strong>non-marketed<\/strong> therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Legal and Regulated Access to Unlicensed Medicines:<\/strong><\/h2>\n\n\n\n<p>Several countries in the <strong>European Union (EU), the Middle East, Asia, Africa, and Latin America<\/strong> have authorized channels to import unlicensed or unapproved drugs for those with life-threatening conditions. These frameworks are typically known as:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Named Patient Program (NPP)<\/li>\n\n\n\n<li><a href=\"https:\/\/ikrispharmainternational.com\/named-patient-program\">Managed Access Program<\/a><\/li>\n\n\n\n<li>Compassionate Use Program<\/li>\n\n\n\n<li>Expanded Access Program<\/li>\n\n\n\n<li>Early Access Program (EAP)<\/li>\n\n\n\n<li>Special Import License (varies by country)<br><\/li>\n<\/ul>\n\n\n\n<p>These mechanisms are for clinicians to access hard-to-find therapies for patients with <strong>rare,<\/strong> <strong>life-threatening, or treatment-resistant conditions<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>How Ikris Pharma International Facilitates Global Access?<\/strong><\/h2>\n\n\n\n<p><strong>Ikris Pharma International<\/strong> operates from its strategic <strong>EU-GDP certified warehouse in Belgium<\/strong>. The company supports physicians, hospitals, wholesalers, and authorized importers in accessing <strong>unlicensed and hard-to-find medicines <\/strong>directly from regulated markets.<\/p>\n\n\n\n<p><strong>Our Access Capabilities Include:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Sourcing medicines approved by the <strong>FDA<\/strong>, <strong>EMA<\/strong>, <strong>MHRA<\/strong>, <strong>TGA<\/strong>, and other authorities<\/li>\n\n\n\n<li>EU-GDP compliant handling, storage, and distribution<\/li>\n\n\n\n<li>Export of specialty, rare-disease, oncology, and orphan medicines<\/li>\n\n\n\n<li>Support for <strong>Named Patient Programs<\/strong> and <strong>Special Import Authorizations<\/strong><\/li>\n\n\n\n<li>Temperature-controlled shipments with validated packaging<\/li>\n\n\n\n<li>Full batch traceability and manufacturer-authentic verification<br><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Treatment Areas Where Unlicensed Medicines Are Commonly Needed<\/strong><\/h2>\n\n\n\n<p>Patients may require unapproved or unlicensed medicines for:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rare diseases \/ orphan conditions<\/strong><\/li>\n\n\n\n<li><strong>Advanced oncology therapies<\/strong><\/li>\n\n\n\n<li><strong>Neurology and genetic disorders<\/strong><\/li>\n\n\n\n<li><strong>Immunology and autoimmune diseases<\/strong><\/li>\n\n\n\n<li><strong>Enzyme replacement therapies<\/strong><\/li>\n\n\n\n<li><strong>Breakthrough biologics and targeted therapies<\/strong><\/li>\n\n\n\n<li>Newly approved <strong>cell &amp; gene therapies<\/strong><strong><br><\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>How the Process Works: Accessing Unapproved Medicines Internationally<\/strong><\/h2>\n\n\n\n<p>Below is a simplified model followed by many countries\u2019 regulatory systems. The actual process generally varies depending on local norms.<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>The treating physician writes a prescription<\/strong> for the unlicensed medicine<\/li>\n\n\n\n<li><strong>Medical justification<\/strong> explaining why local treatments are unsuitable<\/li>\n\n\n\n<li><strong>Import authorization<\/strong> or special permit from the national authority<\/li>\n\n\n\n<li>Medicine is sourced exclusively from a <strong>regulated supply chain<\/strong><\/li>\n\n\n\n<li>EU-GDP-compliant shipment reaches the hospital or authorized importing agency<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Quality, Safety, and Regulatory Compliance:<\/strong><\/h2>\n\n\n\n<p>Even in cases where any medicine is \u201cunlicensed\u201d or not approved in a particular country, it must come from a <strong>globally approved manufacturer<\/strong> and follow all the strict quality guidelines:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Original manufacturer-packaged product<\/li>\n\n\n\n<li>Full documentation support<\/li>\n\n\n\n<li>Batch Certificate of Analysis (CoA)<\/li>\n\n\n\n<li>Temperature logs (if required)<\/li>\n\n\n\n<li>EU-GDP-compliant distribution<br><\/li>\n<\/ul>\n\n\n\n<p>This ensures <strong>authentic, high-quality, and safe<\/strong> access to unlicensed and unapproved drugs for patients across the world.<br><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Conclusion: Helping Patients Get the Medicines They Need, Wherever They Live<\/strong><\/h2>\n\n\n\n<p>Unlicensed and unapproved medicines are extremely important for global healthcare, mainly for those with few or no treatment options. Through regulated access frameworks, physicians can obtain such therapies that are not yet approved in their home country.<\/p>\n\n\n\n<p>With its <strong>EU-GDP certified operations in Belgium<\/strong>, <strong><a href=\"https:\/\/ikrispharmainternational.com\/\">Ikris Pharma International<\/a><\/strong> supports global health systems by ensuring <strong>safe, compliant, and timely access<\/strong> to essential unlicensed medicines\u2014bridging the gap between medical innovation and patient need.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>References:<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.ema.europa.eu\/en\">European Medicines Agency \u2013 Unlicensed Medicines Guidance<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.fda.gov\">U.S. FDA \u2013 Expanded Access Program<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.gov.uk\/mhra\">MHRA UK \u2013 Unlicensed Medicines (Specials)<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.tga.gov.au\">TGA Australia \u2013 Special Access Scheme<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.famhp.be\">Belgium FAMHP \u2013 Regulations for Unlicensed Medicines<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>In some scenarios, patients around the world need unlicensed or unapproved medicines. This happens when standard treatments have failed or are not yet available in their home country. Healthcare is&hellip;<\/p>\n","protected":false},"author":1,"featured_media":134,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[62],"tags":[61,57,59,60,58],"class_list":["post-133","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-import","tag-accessing-unapproved-medicines-internationally","tag-global-access-to-unapproved-drugs","tag-managed-access-program","tag-named-patient-program","tag-unapproved-medicines"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Global Access to Unapproved Drugs - Ikris Pharma International Blog | Insights on Access to Essential Medicines<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Global Access to Unapproved Drugs - Ikris Pharma International Blog | Insights on Access to Essential Medicines\" \/>\n<meta property=\"og:description\" content=\"In some scenarios, patients around the world need unlicensed or unapproved medicines. This happens when standard treatments have failed or are not yet available in their home country. Healthcare is&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/\" \/>\n<meta property=\"og:site_name\" content=\"Ikris Pharma International Blog | Insights on Access to Essential Medicines\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/Ikrispharmanetwork\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-09T12:25:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-12T06:38:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ikrispharmainternational.com\/blog\/wp-content\/uploads\/2025\/12\/image1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"770\" \/>\n\t<meta property=\"og:image:height\" content=\"440\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/ikrispharmainternational.com\/blog\/#\/schema\/person\/773d300b8a86d7c8eb3a443803a98635\"},\"headline\":\"Global Access to Unapproved Drugs\",\"datePublished\":\"2025-12-09T12:25:37+00:00\",\"dateModified\":\"2025-12-12T06:38:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/\"},\"wordCount\":795,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ikrispharmainternational.com\/blog\/#organization\"},\"image\":{\"@id\":\"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ikrispharmainternational.com\/blog\/wp-content\/uploads\/2025\/12\/image1.png\",\"keywords\":[\"Accessing Unapproved Medicines Internationally\",\"Global Access to Unapproved Drugs\",\"Managed Access Program\",\"Named Patient Program\",\"Unapproved medicines\"],\"articleSection\":[\"Import\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/\",\"url\":\"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/\",\"name\":\"Global Access to Unapproved Drugs - Ikris Pharma International Blog | Insights on Access to Essential Medicines\",\"isPartOf\":{\"@id\":\"https:\/\/ikrispharmainternational.com\/blog\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ikrispharmainternational.com\/blog\/wp-content\/uploads\/2025\/12\/image1.png\",\"datePublished\":\"2025-12-09T12:25:37+00:00\",\"dateModified\":\"2025-12-12T06:38:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/#primaryimage\",\"url\":\"https:\/\/ikrispharmainternational.com\/blog\/wp-content\/uploads\/2025\/12\/image1.png\",\"contentUrl\":\"https:\/\/ikrispharmainternational.com\/blog\/wp-content\/uploads\/2025\/12\/image1.png\",\"width\":770,\"height\":440,\"caption\":\"Unlicensed and Unapproved Drugs: Global Access, Regulations & the Role of Ikris Pharma International\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ikrispharmainternational.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Global Access to Unapproved Drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ikrispharmainternational.com\/blog\/#website\",\"url\":\"https:\/\/ikrispharmainternational.com\/blog\/\",\"name\":\"https:\/\/ikrispharmainternational.com\",\"description\":\"Pharma exporter, RLD supplier\",\"publisher\":{\"@id\":\"https:\/\/ikrispharmainternational.com\/blog\/#organization\"},\"alternateName\":\"Ikris Pharma International\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ikrispharmainternational.com\/blog\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ikrispharmainternational.com\/blog\/#organization\",\"name\":\"Ikris Pharma International\",\"url\":\"https:\/\/ikrispharmainternational.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ikrispharmainternational.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ikrispharmainternational.com\/blog\/wp-content\/uploads\/2025\/08\/cropped-ikris-international-logo-2.jpg\",\"contentUrl\":\"https:\/\/ikrispharmainternational.com\/blog\/wp-content\/uploads\/2025\/08\/cropped-ikris-international-logo-2.jpg\",\"width\":240,\"height\":64,\"caption\":\"Ikris Pharma International\"},\"image\":{\"@id\":\"https:\/\/ikrispharmainternational.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ikrispharmanetwork\",\"https:\/\/in.linkedin.com\/company\/ikris-pharma-network\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/ikrispharmainternational.com\/blog\/#\/schema\/person\/773d300b8a86d7c8eb3a443803a98635\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ikrispharmainternational.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/471a0c08eecc1f4803da000761ed45402d76338bf435709f0ea517644586a4ee?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/471a0c08eecc1f4803da000761ed45402d76338bf435709f0ea517644586a4ee?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/ikrispharmainternational.com\/blog\"],\"url\":\"https:\/\/ikrispharmainternational.com\/blog\/author\/beadmin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Global Access to Unapproved Drugs - Ikris Pharma International Blog | Insights on Access to Essential Medicines","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/","og_locale":"en_US","og_type":"article","og_title":"Global Access to Unapproved Drugs - Ikris Pharma International Blog | Insights on Access to Essential Medicines","og_description":"In some scenarios, patients around the world need unlicensed or unapproved medicines. This happens when standard treatments have failed or are not yet available in their home country. Healthcare is&hellip;","og_url":"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/","og_site_name":"Ikris Pharma International Blog | Insights on Access to Essential Medicines","article_publisher":"https:\/\/www.facebook.com\/Ikrispharmanetwork","article_published_time":"2025-12-09T12:25:37+00:00","article_modified_time":"2025-12-12T06:38:11+00:00","og_image":[{"width":770,"height":440,"url":"https:\/\/ikrispharmainternational.com\/blog\/wp-content\/uploads\/2025\/12\/image1.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/#article","isPartOf":{"@id":"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/"},"author":{"name":"admin","@id":"https:\/\/ikrispharmainternational.com\/blog\/#\/schema\/person\/773d300b8a86d7c8eb3a443803a98635"},"headline":"Global Access to Unapproved Drugs","datePublished":"2025-12-09T12:25:37+00:00","dateModified":"2025-12-12T06:38:11+00:00","mainEntityOfPage":{"@id":"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/"},"wordCount":795,"commentCount":0,"publisher":{"@id":"https:\/\/ikrispharmainternational.com\/blog\/#organization"},"image":{"@id":"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/#primaryimage"},"thumbnailUrl":"https:\/\/ikrispharmainternational.com\/blog\/wp-content\/uploads\/2025\/12\/image1.png","keywords":["Accessing Unapproved Medicines Internationally","Global Access to Unapproved Drugs","Managed Access Program","Named Patient Program","Unapproved medicines"],"articleSection":["Import"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/","url":"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/","name":"Global Access to Unapproved Drugs - Ikris Pharma International Blog | Insights on Access to Essential Medicines","isPartOf":{"@id":"https:\/\/ikrispharmainternational.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/#primaryimage"},"image":{"@id":"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/#primaryimage"},"thumbnailUrl":"https:\/\/ikrispharmainternational.com\/blog\/wp-content\/uploads\/2025\/12\/image1.png","datePublished":"2025-12-09T12:25:37+00:00","dateModified":"2025-12-12T06:38:11+00:00","breadcrumb":{"@id":"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/#primaryimage","url":"https:\/\/ikrispharmainternational.com\/blog\/wp-content\/uploads\/2025\/12\/image1.png","contentUrl":"https:\/\/ikrispharmainternational.com\/blog\/wp-content\/uploads\/2025\/12\/image1.png","width":770,"height":440,"caption":"Unlicensed and Unapproved Drugs: Global Access, Regulations & the Role of Ikris Pharma International"},{"@type":"BreadcrumbList","@id":"https:\/\/ikrispharmainternational.com\/blog\/global-access-to-unapproved-drugs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ikrispharmainternational.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Global Access to Unapproved Drugs"}]},{"@type":"WebSite","@id":"https:\/\/ikrispharmainternational.com\/blog\/#website","url":"https:\/\/ikrispharmainternational.com\/blog\/","name":"https:\/\/ikrispharmainternational.com","description":"Pharma exporter, RLD supplier","publisher":{"@id":"https:\/\/ikrispharmainternational.com\/blog\/#organization"},"alternateName":"Ikris Pharma International","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ikrispharmainternational.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ikrispharmainternational.com\/blog\/#organization","name":"Ikris Pharma International","url":"https:\/\/ikrispharmainternational.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ikrispharmainternational.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/ikrispharmainternational.com\/blog\/wp-content\/uploads\/2025\/08\/cropped-ikris-international-logo-2.jpg","contentUrl":"https:\/\/ikrispharmainternational.com\/blog\/wp-content\/uploads\/2025\/08\/cropped-ikris-international-logo-2.jpg","width":240,"height":64,"caption":"Ikris Pharma International"},"image":{"@id":"https:\/\/ikrispharmainternational.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ikrispharmanetwork","https:\/\/in.linkedin.com\/company\/ikris-pharma-network"]},{"@type":"Person","@id":"https:\/\/ikrispharmainternational.com\/blog\/#\/schema\/person\/773d300b8a86d7c8eb3a443803a98635","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ikrispharmainternational.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/471a0c08eecc1f4803da000761ed45402d76338bf435709f0ea517644586a4ee?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/471a0c08eecc1f4803da000761ed45402d76338bf435709f0ea517644586a4ee?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/ikrispharmainternational.com\/blog"],"url":"https:\/\/ikrispharmainternational.com\/blog\/author\/beadmin\/"}]}},"_links":{"self":[{"href":"https:\/\/ikrispharmainternational.com\/blog\/wp-json\/wp\/v2\/posts\/133","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ikrispharmainternational.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ikrispharmainternational.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ikrispharmainternational.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ikrispharmainternational.com\/blog\/wp-json\/wp\/v2\/comments?post=133"}],"version-history":[{"count":6,"href":"https:\/\/ikrispharmainternational.com\/blog\/wp-json\/wp\/v2\/posts\/133\/revisions"}],"predecessor-version":[{"id":145,"href":"https:\/\/ikrispharmainternational.com\/blog\/wp-json\/wp\/v2\/posts\/133\/revisions\/145"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ikrispharmainternational.com\/blog\/wp-json\/wp\/v2\/media\/134"}],"wp:attachment":[{"href":"https:\/\/ikrispharmainternational.com\/blog\/wp-json\/wp\/v2\/media?parent=133"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ikrispharmainternational.com\/blog\/wp-json\/wp\/v2\/categories?post=133"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ikrispharmainternational.com\/blog\/wp-json\/wp\/v2\/tags?post=133"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}